L. Lazar et al., Sexual precocity in boys: Accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height, J CLIN END, 86(9), 2001, pp. 4127-4132
The indication for GnRH analog treatment in boys with central sexual precoc
ity is based mainly on the age of onset of puberty. Our aim was to determin
e whether the rate of pubertal progression should also be taken into consid
eration.
Included in the study were 81 boys with central sexual precocity: 27 with t
rue precocious puberty (onset at <9 yr) and 54 with early puberty (onset at
9-10.5 yr). At the time of analysis, all had completed puberty, and 66 (22
central precocious puberty, 44 early puberty) had achieved final height. P
rogression of puberty (Tanner stage 2 to 3) was accelerated (0.5-1.32 yr) i
n 42 boys (16 central precocious puberty, 26 early puberty) and slow (1.7-2
.9 yr) in 39 (11 central precocious puberty, 28 early puberty). The boys wi
th accelerated puberty had significantly elevated T levels (central precoci
ous puberty and early puberty, P < 0.001), faster growth rate (change in he
ight SD score/duration: central precocious puberty, P < 0.05; early puberty
, P < 0.01), and faster bone maturation rate (change in bone age/ duration:
central precocious puberty, P < 0.05; early puberty, P < 0.001). All 42 bo
ys with accelerated puberty were treated with GnRH analog for 2.3-4.2 yr; t
he duration to completion of puberty and the height gain after therapy was
discontinued were similar for the boys with central precocious puberty and
early puberty. The 39 boys with slow puberty received no treatment and had
a prolonged course of puberty (central precocious puberty, 5.05 +/- 0.3 yr;
early puberty, 4.72 +/- 0.77 yr; average normal, 3.5 yr). The final height
achieved in the 35 (11 central precocious puberty, 24 early puberty) untre
ated boys was within the range of their respective target height. The 31 (1
1 central precocious puberty, 20 early puberty) treated boys also achieved
their genetic target height. Predictions based on the Bayley-Pinneau method
at Tanner stage 3 for all boys and at discontinuation of therapy for treat
ed boys overestimated the achieved final height (P < 0.001).
In conclusion, boys with sexual precocity, whether central precocious puber
ty or early puberty, may have either accelerated or slow pubertal developme
nt. The decision to institute suppressive therapy should be based also on t
he rate of pubertal progression. Treatment should be offered only to those
(either central precocious puberty or early puberty) with accelerated growt
h and bone maturation rates and rapid increase in T levels. Suppression the
rapy apparently converts accelerated puberty into nonsustained slow puberty
and probably prevents compromised final height.